4//SEC Filing
Wei Lin 4
Accession 0001610717-25-000351
CIK 0001628171other
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 4:39 PM ET
Size
4.7 KB
Accession
0001610717-25-000351
Insider Transaction Report
Form 4
Wei Lin
Chief Medical Officer
Transactions
- Sale
Common Stock
2025-09-16$45.82/sh−2,160$98,982→ 88,339 total
Footnotes (2)
- [F1]Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025.
- [F2]Includes 58,850 restricted stock units.
Documents
Issuer
Revolution Medicines, Inc.
CIK 0001628171
Entity typeother
Related Parties
1- filerCIK 0001872772
Filing Metadata
- Form type
- 4
- Filed
- Sep 17, 8:00 PM ET
- Accepted
- Sep 18, 4:39 PM ET
- Size
- 4.7 KB